Een nieuwe manier van aangrijipen in het proces van virusvermeerdering: HIV-adsorptie-en-fusie-inhibitoren

M. W. Rautenberg, A. D.R. Huitema, J. H. Beijnen

Onderzoeksoutput: Bijdrage aan tijdschriftKort overzichtpeer review

Samenvatting

Currently treatment of HIV-1 infected patients consists of combination therapy with antiretroviral agents from three different classes (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors). Although combination therapy with these agents leads to a strong reduction in morbidity and mortality, the occurrence of side effects and the development of resistance limits the long term use of these agents. Therefore, there is a strong demand for new antiretroviral agents with a new target in virus replication. One of the most promising new groups consists of the fusion inhibitors. These compounds inhibit the fusion of HIV with the host cell and, therefore, prevent infection of the host cell. Currently, several compounds, which inhibit the fusion process at several stages, are in development. This article provides a concise overview of these compounds.

Vertaalde titel van de bijdrageHIV adsorption and fusion inhibitors. A new way of drug targeting in the process of virus replication
Originele taal-2Nederlands
Pagina's (van-tot)796-801
Aantal pagina's6
TijdschriftPharmaceutisch Weekblad
Volume137
Nummer van het tijdschrift22
StatusGepubliceerd - 31 mei 2002
Extern gepubliceerdJa

Trefwoorden

  • Anti-HIV agents
  • Drug design
  • Drug resistance
  • HIV
  • Viral fusion proteins
  • Virus replication

Vingerafdruk

Duik in de onderzoeksthema's van 'Een nieuwe manier van aangrijipen in het proces van virusvermeerdering: HIV-adsorptie-en-fusie-inhibitoren'. Samen vormen ze een unieke vingerafdruk.

Citeer dit